top of page
  • Writer's pictureKirk Hartley

Fall Out from Myriad – New Gene Patent Testing and Prices Are Starting to Fall

Quest is out with news that it will sell a BRACA gene patent test for 40% less than Myriad’s BRACA gene patent test. Meanwhile, Mryiad and others remain in litigation, with Quest having sued Myriad just prior to announcing the new test.

#Cancer

1 view0 comments

Recent Posts

See All

The litigation industry is global. The latest example is the start of RoundUp/glyphosate litigation in Australia, as described in this June 3,  2019 article in the Brisbane Times.

bottom of page